Claudia Beqaj, Executive Director, Dermatology, Boehringer Ingelheim
Over the past year, Claudia Beqaj has led her team through the successful launch of Boehringer Ingelheim’s Spevigo, which was FDA approved in September 2022 for the treatment of generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL- 36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP.
Claudia and her team were charged with executing a successful launch strategy to educate, inform, and inspire dermatologists, patients, and caregivers. In one instance, she partnered with Confideo to design, develop, and deploy two visceral and highly visual unbranded immersive multimedia tactical integrations. One was a clinical presentation in full 3D that enabled customers to distinguish GPP contextually and clearly. The other involved two holographic patient vignettes that equally conveyed the visual severity of the condition in a way never done before, while also evoking empathy and understanding to reinforce the impact and effect of GPP on patients.
Following the success of the initial roll out, Claudia and team developed additional branded elements that engaged audiences in a visual way by displaying the severity of the disease and benefits of Spevigo.
The programs have seeded and supported the launch and have been recognized with numerous industry awards including two Telly Awards, two Communicator Awards, and one Vega Digital Award, among others.
